A detailed history of Ensign Peak Advisors, Inc transactions in Maxcyte, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 59,013 shares of MXCT stock, worth $259,067. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,013
Previous 59,013 -0.0%
Holding current value
$259,067
Previous $231,000 0.87%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$3.94 - $5.38 $11,729 - $16,016
-2,977 Reduced 4.8%
59,013 $247,000
Q4 2023

Feb 14, 2024

BUY
$2.6 - $5.24 $9,360 - $18,864
3,600 Added 6.17%
61,990 $291,000
Q1 2023

May 15, 2023

BUY
$4.03 - $5.89 $79,794 - $116,622
19,800 Added 51.31%
58,390 $289,000
Q4 2022

Feb 13, 2023

BUY
$4.92 - $7.4 $93,726 - $140,970
19,050 Added 97.49%
38,590 $210,000
Q1 2022

May 16, 2022

BUY
$5.26 - $10.84 $102,780 - $211,813
19,540 New
19,540 $137,000

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $447M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.